Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.42 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.40 |
| ▸ | AKT1 | P31749 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19900193 | 0.94 | HIPK2 (0.41) | SMYD3CYP3A4HIPK2KDM2BHDAC3 | |
| SCHEMBL28486284 | 0.81 | HIPK2 (0.53) | SMYD3CYP3A4HIPK2KDM2BIMPDH2 | |
| SCHEMBL28478142 | 0.79 | CES2 (0.55) | CYP3A4 | |
| SCHEMBL13616938 | 0.78 | GABRA1 (0.35) | CYP3A4IMPDH2CYP19A1 | |
| SCHEMBL9750232 | 0.77 | SMYD3 (0.45) | SMYD3CYP3A4HIPK2KDM2BIMPDH2 | |
| SCHEMBL113378 | 0.75 | SMYD3 (0.55) | SMYD3CYP3A4HIPK2KDM2BIMPDH2 | |
| SCHEMBL29489099 | 0.75 | SMYD3 (0.55) | SMYD3CYP3A4HIPK2KDM2BIMPDH2 | |
| SCHEMBL14699587 | 0.75 | NAPRT (0.46) | CYP3A4 | |
| SCHEMBL29522657 | 0.74 | AR (0.62) | SMYD3CYP3A4HIPK2KDM2BIMPDH2 | |
| Hydrochloric Acid SCHEMBL7557776 | 0.74 | SMYD3 (0.54) | SMYD3CYP3A4HIPK2KDM2BIMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145913-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-11685722-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685722-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| CN-115215807-A | Inhibition of OLIG2 activity | 科泰纳制药公司 | 2022-10-21 | — | — | CN | disclosed |
| US-11242323-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242323-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20200407329-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2020-12-31 | — | — | US | disclosed |
| EP-3504195-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| CN-109843868-A | inhibition of OLIG2 activity | 科泰纳制药公司 | 2019-06-04 | — | — | CN | disclosed |
| WO-2018039621-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | SMYD3 2207/4885CYP3A4 4877/4885HIPK2 91/4885 |
| US-11685722-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | SMYD3 2207/4885CYP3A4 4877/4885HIPK2 91/4885 |
| US-12145913-B2 | Inhibition of Olig2 activity | POU2F2, POU2F1, PLP2 | SMYD3 1574/4885CYP3A4 4823/4885HIPK2 153/4885 |
| US-11242323-B2 | Inhibition of OLIG2 activity | POU2F2, ING2, PAX2 | SMYD3 1297/4885CYP3A4 4859/4885HIPK2 162/4885 |
| US-20200407329-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | SMYD3 2207/4885CYP3A4 4877/4885HIPK2 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.